Martingale Asset Management L P Raises Stock Holdings in Gilead Sciences, Inc. $GILD

Martingale Asset Management L P lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 193,921 shares of the biopharmaceutical company’s stock after acquiring an additional 21,153 shares during the period. Martingale Asset Management L P’s holdings in Gilead Sciences were worth $23,802,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the stock. Van Lanschot Kempen Investment Management N.V. grew its position in Gilead Sciences by 1.2% during the fourth quarter. Van Lanschot Kempen Investment Management N.V. now owns 267,702 shares of the biopharmaceutical company’s stock valued at $32,858,000 after buying an additional 3,200 shares during the period. Korea Investment CORP lifted its holdings in Gilead Sciences by 0.5% during the fourth quarter. Korea Investment CORP now owns 1,358,423 shares of the biopharmaceutical company’s stock valued at $166,733,000 after purchasing an additional 7,105 shares during the last quarter. Banco Santander S.A. lifted its holdings in Gilead Sciences by 96.9% during the fourth quarter. Banco Santander S.A. now owns 261,844 shares of the biopharmaceutical company’s stock valued at $32,139,000 after purchasing an additional 128,848 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in Gilead Sciences by 0.5% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,209,202 shares of the biopharmaceutical company’s stock valued at $148,417,000 after purchasing an additional 5,528 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its holdings in Gilead Sciences by 57.4% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 126,150 shares of the biopharmaceutical company’s stock valued at $15,484,000 after purchasing an additional 46,000 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.2%

Shares of Gilead Sciences stock opened at $125.59 on Friday. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29. The company has a market cap of $155.93 billion, a price-to-earnings ratio of 17.11 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company’s 50-day moving average price is $133.16 and its 200-day moving average price is $134.28.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen, a potentially important catalyst for Gilead’s HIV franchise and long-term growth. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Bernstein reiterated a Buy view on Gilead, and unusual call option activity suggests traders are positioning for upside ahead of additional catalysts. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: The company advanced a Phase 2 study of denikitug in difficult-to-treat colorectal cancer, adding another pipeline readout that could broaden Gilead’s oncology prospects. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Positive Sentiment: Gilead is donating remdesivir to Uganda to support Ebola response efforts, reinforcing the company’s reputation in infectious disease care and public-health leadership. Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
• Neutral Sentiment: Gilead and the Gilead Foundation announced about $3 million in funding with the National AIDS Memorial for HIV/AIDS education and leadership initiatives, a brand-building effort with limited near-term earnings impact. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
• Neutral Sentiment: Erste Group slightly lowered its FY2026 earnings estimate for Gilead, but the revision was small and stays close to the broader loss expectations already in place. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Negative Sentiment: Recent commentary suggests Gilead’s stock has pulled back from its 50-day and 200-day moving averages, indicating some short-term technical pressure despite the positive pipeline news.

Analyst Upgrades and Downgrades

Several research firms have commented on GILD. Daiwa Securities Group dropped their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Leerink Partners dropped their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Barclays began coverage on shares of Gilead Sciences in a report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective on the stock. Finally, Mizuho upped their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $156.93.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 68,000 shares of company stock worth $9,047,570. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.